Rathbones Group PLC Grows Position in Stryker Corporation $SYK

Rathbones Group PLC increased its holdings in Stryker Corporation (NYSE:SYK) by 22.0% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 267,569 shares of the medical technology company’s stock after buying an additional 48,304 shares during the quarter. Rathbones Group PLC’s holdings in Stryker were worth $87,920,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of SYK. Sankala Group LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $26,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker during the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker in the fourth quarter worth approximately $28,000. Institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

Stryker Stock Up 0.2%

SYK opened at $326.41 on Monday. The firm’s 50 day simple moving average is $317.28 and its two-hundred day simple moving average is $334.73. The company has a market capitalization of $125.13 billion, a PE ratio of 33.82, a PEG ratio of 2.08 and a beta of 0.76. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $401.99. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.01 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Tuesday, June 30th. Stryker’s payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SYK. BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday. Citigroup cut their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. UBS Group initiated coverage on Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective for the company. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Wolfe Research set a $375.00 target price on Stryker in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $387.88.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.